Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Flunisolide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 6/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.98 |
| ▸ | PGR | P06401 | 7/20 | 0.98 |
| ▸ | LMNA | P02545 | 6/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 4/20 | 0.98 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.98 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.98 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.98 |
| ▸ | HTR1A | P08908 | 1/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.98 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.98 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.69 |
| ▸ | AR | P10275 | 4/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.53 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Flunisolide SCHEMBL22527648 | 1.00 | CYP3A4 (0.98) | CYP3A4PGRNR3C1LMNAABCB11 | |
| Flunisolide SCHEMBL6830317 | 1.00 | CYP3A4 (0.98) | CYP3A4PGRNR3C1LMNAABCB11 | |
| Flunisolide SCHEMBL4351 | 0.99 | CYP3A4 (1.00) | CYP3A4PGRNR3C1LMNAABCB11 | |
| Flunisolide SCHEMBL13026142 | 0.99 | CYP3A4 (1.00) | CYP3A4PGRNR3C1LMNAABCB11 | |
| Flunisolide SCHEMBL5493687 | 0.99 | CYP3A4 (1.00) | CYP3A4PGRNR3C1LMNAABCB11 | |
| Flunisolide SCHEMBL8810954 | 0.99 | CYP3A4 (1.00) | CYP3A4PGRNR3C1LMNAABCB11 | |
| Flunisolide SCHEMBL66051 | 0.99 | CYP3A4 (1.00) | CYP3A4PGRNR3C1LMNAABCB11 | |
| Flunisolide SCHEMBL5187487 | 0.99 | CYP3A4 (1.00) | CYP3A4PGRNR3C1LMNAABCB11 | |
| Flunisolide SCHEMBL13662143 | 0.99 | CYP3A4 (1.00) | CYP3A4PGRNR3C1LMNAABCB11 | |
| Flunisolide SCHEMBL30994800 | 0.99 | CYP3A4 (1.00) | CYP3A4PGRNR3C1LMNAABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 314 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220054553-A1 | METHODS OF TREATING ISCHEMIA | FATE THERAPEUTICS INC (US) | 2022-02-24 | — | — | US | claimed |
| US-11052118-B2 | Enhanced stem cell composition | FATE THERAPEUTICS, INC. (US) | 2021-07-06 | — | — | US | claimed |
| US-10980838-B2 | Methods of treating ischemia | FATE THERAPEUTICS, INC. (US) | 2021-04-20 | — | — | US | claimed |
| EP-3785767-A1 | ENHANCED STEM CELL COMPOSITION | Fate Therapeutics, Inc. (US) | 2021-03-03 | — | — | EP | claimed |
| EP-2785834-B1 | ENHANCED STEM CELL COMPOSITION | FATE THERAPEUTICS INC (US) | 2020-09-23 | — | — | EP | claimed |
| US-20200172870-A1 | CELLS WITH INCREASED IMMUNO-REGULATORY PROPERTIES AND METHODS FOR THEIR USE AND MANUFACTURE | FATE THERAPEUTICS INC (US) | 2020-06-04 | — | — | US | claimed |
| US-20190119635-A1 | MODULATION OF T LYMPHOCYTES | FATE THERAPEUTICS, INC. | 2019-04-25 | — | — | US | claimed |
| US-20190111085-A1 | ENHANCED STEM CELL COMPOSITION | FATE THERAPEUTICS INC (US) | 2019-04-18 | — | — | US | claimed |
| US-20190015454-A1 | METHODS OF TREATING ISCHEMIA | FATE THERAPEUTICS INC (US) | 2019-01-17 | — | — | US | claimed |
| US-10172888-B2 | Enhanced stem cell composition | FATE THERAPEUTICS, INC. (US) | 2019-01-08 | — | — | US | claimed |
| US-20060216353-A1 | Nanoparticulate corticosteroid and antihistamine formulations | ELAN PHARMA INTERNATIONAL LIMITED | 2006-09-28 | — | — | US | claimed |
| WO-2006099591-A1 | NANOPARTICULATE LEUKOTRIENE RECEPTOR ANTAGONIST/CORTICOSTEROID FORMULATIONS | ELAN PHARMA INTERNATIONAL LIMITED (IE) | 2006-09-21 | — | — | WO | claimed |
| US-20060127322-A1 | Stable pharmaceutical Budesonide preparation for producing propellant-free aerosols | BOEHRINGER INGELHEIM KG (DE) | 2006-06-15 | — | — | US | claimed |
| US-20030165435-A1 | Using ethanol solvent | BOEHRINGER INGELHEIM KG (DE) | 2003-09-04 | — | — | US | claimed |
| US-20020141944-A1 | Stable pharmaceutical budersonide preparation for producing propellant-free aerosols | FREUND BERNHARD (DE) | 2002-10-03 | — | — | US | claimed |
| EP-0835098-B1 | NEW, STABLE MEDICINAL COMPOSITIONS FOR GENERATING PROPELLANT-FREE AEROSOLS | BOEHRINGER INGELHEIM PHARMA (DE) | 2002-09-04 | — | — | EP | claimed |
| US-6129905-A | Aerosol formulations containing a sugar as a dispersant | AEROPHARM TECHNOLOGY, INC. | 2000-10-10 | — | — | US | claimed |
| EP-0246652-B1 | AQUEOUS STEROID FORMULATIONS FOR NASAL ADMINISTRATION | SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) | 1991-07-17 | — | — | EP | claimed |
| US-4782047-A | Aqueous steroid formulations for nasal administration | SYNTEX PHARMACEUTICALS INTERNATIONAL LTD. (BM) | 1988-11-01 | — | — | US | claimed |
| EP-0246652-A2 | Aqueous steroid formulations for nasal administration | SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) | 1987-11-25 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060216353-A1 | Nanoparticulate corticosteroid and antihistamine formulations | HRH1, SERPINA6, HRH4 | NR3C1 6/4885CYP3A4 898/4885PGR 1720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.